[Ferro-folgamma--a good alternative in the treatment of iron deficiency anemia and depleted iron stores in pregnant women].
OBJECTIVE
To study the effect of different therapeutical regimens of Ferro-Folgamma, in pregnant patients with iron deficiency anemia.


METHODS
22 pregnant patients between 20 and 35 week of gestation (mean 29 gestational week) with hemoglobin levels between 83.1-106 g/l were included. They were divided in two groups: group 1 included patients with hemoglobin levels up to 100g/l and group 2--with hemoglobin levels between 100 and 110. The dosage of the preparation in group 1 was 1 tablet Ferro-Folgamma tid for 40 days, and 1 tablet Ferro-Folgamma bid for the same period. Blood samples were taken four times during the study on day 0, 10th day, 20th day and in the week after the 40th completed day of therapy. The samples were tested for CBC, iron, transferine, feritine, folic acid. All patients were given complete information about the possible risks of iron deficiency anemia during pregnancy and parturition.


RESULTS
The mean hemoglobin level at initiation of treatment was 91.22 g/l (day 0). After initiation of treatment the the following rise in hemoglobin levels was detected 10th day - 103.8 g/l, 20th day - 112.6 g/l, after the 40th completed day - 136.0 g/l. The mean levels of the rest of hematological parameters were, day 0 - Er - 3.25 mln/microl, Fe - 7.53 micromol/l, transferine - 3.65 gr/l, feritine - 15.02 ngr/ml, folic acid - 14.08 ng/ml, vit. B12 - 219.68 pg/ml; 10th day - Er- 3.5 mln/microl, Fe - 14. 12 micromol/l; 20th day - Er - 4.10 mln/microl, Fe - 20.46 micromol/l; 40th completed day - Er- 4.69 mln/microl, Fe - 13.12 micromol/l, transferine - 3.82 gr/l, feritine - 27.42 ngr/ml, folic acid - 15.67 ng/ml, vit. B12 - 484.52 pg/ml respectively.


CONCLUSIONS
Oral treatment with Ferro-Folgamma, according the described dosage regimen, demonstrates its fast and stable effect in treatment of moderate iron deficiency and recovery of depleted iron pool in pregnant patients as well. It could be administered as a prophylactic preparation for borderline anemic states.
I
I
Sigridov
S
S
Ivanov
D018798:Anemia, Iron-Deficiency / Q000097:blood / Q000188:drug therapy*; D001205:Ascorbic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D005296:Ferrous Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D005492:Folic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D005865:Gestational Age; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D019189:Iron Metabolism Disorders / Q000097:blood / Q000188:drug therapy; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000097:blood / Q000188:drug therapy*; D016896:Treatment Outcome
D004338:Drug Combinations; D005296:Ferrous Compounds; D006454:Hemoglobins; C020748:ferrous sulfate; D005492:Folic Acid; D001205:Ascorbic Acid